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ABSTRACT 
 
Background: Patients with coronary heart disease (CHD) who have received standard therapy to 
the fullest, are still at risk for further cardiovascular events. This is likely because the standard 
therapy fails to inhibit some inflammatory pathways and platelet aggregation which implies the 
disease. This study aimed to determine the effect of colchicine on reducing levels of high sensitive 
c-reactive protein (HsCRP) and mean platelet volume (MPV) in patients with Acute Myocardial 
Infarction (IMA) in the Intensive Cardiovascular Unit (ICVCU) Dr. Moewardi Hospital, Surakarta. 
Subjects and Method: Experimental study was conducted with pre and post design. The study 
was conducted from November 1 to December 31, 2016. A sample of 32 patients with Acute 
Myocardial Infarction was divided into two groups. The control group was given a placebo and the 
treatment group was given colchicine 0.5 mg orally for 5 days. Statistical analysis was done using 
two mean different tests with dependent t-test or Mann-Whitney and two mean analysis paired 
using independent t test or Wilcoxon.  
Results: The HsCRP delta level in colchicine group (mean = 3.82; SD = 2.20) was higher than 
control group (mean = 0.57; SD = 3.12) and it was statistically significant (p<0.001). The delta 
MPV levels in colchicine group (mean = 2.01; SD = 1.16) were higher than control group (mean = 
0.64; SD = 0.83) and it was statistically significant (p = 0.001). 
Conclusions: The administration of 0.5 mg colchicine by oral for 5 days was associated with 
levels of HsCRP and MPV among IMA patients. 
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BACKGROUND 
Coronary heart disease (CHD) according to 
the 2013 Indonesian Ministry of Health's 
Basic Health Research causes the highest 
mortality in Indonesian population (Indo-
nesian Agency for Health Research and 
Development Ministry of Health, 2013). 
CHD patients who have received standard 
therapy to the fullest, are still at risk for 
further cardiovascular events, this is likely 
due to standard therapy failing to inhibit 
some inflammatory pathways that implicate 
the disease (Nidorf et al., 2013). Acute 
coronary syndrome (SKA ) associated with 
a systemic inflammatory response in which 
acute plasma protein increases, including 
C-reactive protein (CRP). Increased plasma 
CRP levels are associated with worsening 
SKA output and risk stratification of death 
and heart failure (Orn et al., 2009). Sichiele 
et al. in 2009 concluded that in IMA 
patients, high CRP levels were an indepen-
dent predictor of death for 30 days (Schiele 
et al., 2009). 
Mean platelet volume (MPV) is the 
measurement most often used to assess 
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platelet size. Larger volume platelets con-
tain more prothrombotic material including 
thromboxane A2 and B2 thromboxane, P-
selectin and more glycoprotein IIb / IIIa 
receptors (Bergoli et al., 2014). In patients 
with mediterranean fever who are treated 
with colchicine there is a decrease in MPV 
(Deftereos et al., 2013a). 
Colchicine provides a therapeutic 
effect through interference with several 
stages of the inflammatory process (Defte-
reos et al., 2013 and Deftereos et al., 2014). 
In 2004, the Food Drug Administra-
tion (FDA) approved colchicine for the 
treatment of Mediterranean fever and acute 
gout and prophylaxis of gout arthritis. 
Colchicine is currently also used as second-
line therapy for the treatment of pericar-
ditis (Deftereos, et al. 2013). A study con-
ducted by Scehjerning et al. 2007 aimed to 
evaluate whether low-dose colchicine as an 
anti-inflammatory therapy can reduce 
HsCRP levels in stable CHD patients (Sceh-
jerning et al., 2013). Cyclicin is known to 
inhibit neutrophil adhesion to vascular 
endothelium. In addition, it also increases 
the levels of cyclic adenosine monophos-
phate leukocyte, inhibits the production of 
interleukin-1 (IL-1) by activated neutrophils 
and inhibits tumor necrosis factor alpha 
(TNF-α) receptors in macrophages and 
endothelial cells. Colchicine can inhibit 
activation of NLRP3 inflammasome protein 
complex which cleaves caspase-1 proteo-
lysis and causes proinflammatory cytokines 
IL-1b and IL-18 (Terteltaub, 2009). 
The aim of this study is to determine 
the effect of oral administration of colchi-
cine 0.5 mg for 5 days on decreasing levels 
of high sensitive CRP (HsCRP) and plate-
lete volume (MPV) in IMA patients. 
 
 
SUBJECTS AND METHOD 
This was a randomized control trial study. 
A sample of 32 IMA patients aged 18 to 75 
years at Dr. Moerwardi hospital, Surakarta, 
Central Java, from November 1 to Decem-
ber 31, 2016 was chosen by random sam-
pling. The exclusion criteria were patients 
with cardiogenic shock or severe heart 
failure, Chronic Liver Disease, Infection, 
Malignancy, and previous Colchicine treat-
ment. The sample was divided into 2 
groups. The treatment group was given 
colchicine 0.5 mg orally for 5 days. The 
control group was given a placebo. 
Antecubial venous blood was taken to 
examine HsCRP and MPV, processing, 
storing blood samples and MPV and HsCRP 
examinations carried out by officers from 
Dr. MoewardiHospital Clinical Laboratory. 
The data analysis was conducted 
using different mean tests. To find out the 
difference in mean between treatment 
groups and controls before and after treat-
ment, an independent sample t test was 
used if the data distribution was normal (if 
it is not normal, the Mann Whitney test is 
used). 
This study has received permission 
from the Ethical Clearance Committee of 
the Dr. Moewardi Hospital Research Ethics 
Committee / Surakarta UNS FK. 
 
RESULTS 
There were no significant differences 
between treatment and control groups on 
variables: age, gender, diagnosis of STEMI 
or NSTEMI, administration of strepto-
kinase, use of ACE inhibitors, use of Beta 
Blockers, and risk factors for IMA such as 
hypertension, diabetes, smoking, drinking 
alcohol, and dyslipidemia and CKMB and 
troponin I levels, IMA degrees according to 
the KILLIP class. 
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Table 1. Characteristics of IMA patients 
Independent 
variables 
Treatment 
(n=16) 
Control 
(n = 16) p 
Mean / Total (%) Mean/ Total (%) 
Age 57.87 52.87 0.178 
Gender 
Male 14 (44) 14 (44) 
1 
Female 2 (6) 2 (6) 
Diagnosis 
STEMI 10 (31) 13(41) 
0.238 
NSTEMI 6 (19) 3 (9) 
Streptokinase 6 (19) 6 (19) 1 
ACE Inhibitor 11 (34) 8 (25) 0.280 
Beta Blocker 15 (47) 15 (47) 1 
Statin 16(50) 16(50) 1 
Hypertension 8 (25) 7 (22) 0.723 
Diabetes 3 (9) 4 (13) 0.669 
Smoking 13 (41) 10 (31) 0.238 
Alcohol 1 (3) 1 (3) 1 
Dyslipidemia 3 (9) 1 (3) 0.238 
KILLIP 
1 10 (31) 11 (34) 
0.718 
2 6 (19) 5 (16) 
CKMB 33.44 64.61 0.897 
Troponin I 3.42 9.42 0.138 
 
The 2 mean difference test between 
HsCRP level (p = 0.056) and MPV value (p 
= 0.098) between the control group and the 
treatment group before colchicine adminis-
tration showed no significant differences 
(Table 2). 
Table 2. Comparison of HsCRP and MPV levels before treatment 
Independent 
Variables 
Treatment Control 2 Mean Difference  Test 
Mean ±SD Mean ±SD SE p CI 95% 
HsCRP 6.13±2.65 4.78±3.45 16.50 0.056 0.13 to 0.01 
MPV 9.15±0.95 8.63±0.95 0.31 0.098 -1.15 to 0.10 
 
After the administration of oral col-
chicine 0.5 mg for 5 days, there were signi-
ficant differences in HsCRP (delta HsCRP) 
and MPV (delta MPV) levels between the 
treatment group and the control group 
before and after colchicine (Table 3). 
Table 3. Comparison of Delta-HsCRP and Delta-MPV in Control and Treatment 
Groups 
Variables Treatment Control 2 Mean Difference  Test 
Mean ±SD Mean ±SD SE p CI 95% 
Delta 
HsCRP 
3.82±2.20 0.57±3.12 26.53 <0.001 0.01 to 0.09 
Delta 
MPV 
-2.01±1.16 0.64±0.83 0.36 0.001 0.64 to 2.07 
Delta-HsCRP, the difference between HsCRP levels before and after colchicine. 
Delta-MPV, the difference in MPV values before and after colchicine.  
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DISCUSSION 
The results of this study showed that there 
were significant differences in HsCRP levels 
after treatment (giving colchicine 0.5 mg 
for 5 days) between the control group and 
the treatment group. There was a signi-
ficant decrease in HsCRP (delta HsCRP) 
levels between the control group and the 
treatment group, whereas the HsCRP level 
before treatment there was no significant 
difference between the control group and 
Delta HsCRP treatment was the difference 
in HsCRP levels before treatment and after 
treatment. The results of this study indi-
cated that the administration of colchicine 
can significantly reduce HsCRP levels in 
patients with acute myocardial infarction. 
Previous studies have only focused on 
giving colchicine to patients with stable 
coronary heart disease, no one has exa-
mined the effects of colchicine on the acute 
phase in IMA patients. 
The results of this study were in 
accordance with Nidorf and Thomson 
(2007) which added colchicine to patients 
with stable coronary heart disease who had 
been given standard therapy, concluded 
that administration of colchicine can reduce 
HsCRP levels in patients with stable Coro-
nary Heart Disease (Nidorf and Thompson, 
2007) Nidorf et al. (2013), reported that 
giving colchicine by 0.5 mg to standard 
therapy in patients with stable Coronary 
Heart Disease can provide secondary pre-
vention, so that colchicine can reduce the 
risk of cardiovascular events such as the 
occurrence of IMA, sudden death and 
stroke in patients with stable Coronary 
Heart Disease (Nidorf et al., 2013). The 
results of this study were in line with pre-
vious studies which stated that colchicine 
can reduce HsCRP levels both in conditions 
of stable coronary heart disease and in the 
acute phase of acute myocardial infarction. 
(Giannopoulos et al, 2015; Kaski, 2010; 
Nann, 2014; Molad, 2012). 
The mechanism for decreasing 
HsCRP levels in colchicine was related to 
the effect of colchicine on suppressing cas-
pase-1 activity, the enzymatic component of 
the nucleotide-binding oligomerization 
domain (NOD-like receptor) receptor. The 
suppression of Caspase-1 blocked the con-
version of pro-interleukin (IL) -1b to active 
IL-1b, resulting in a reduction in cytokines 
such as tumor necrosis factor-alpha (TNF-
a) and IL-6 (Slobodnick et al., 2015). IL-6 
stimulated CRP production in the liver 
(Kumar and Cannon, 2009). The results of 
this study were in accordance with the 
theoretical concept of giving colchicine can 
suppress caspase 1 activity, there was a 
decrease in the level of IL-6 which ultima-
tely caused a decrease in HsCRP levels. 
The findings of this study also showed 
that there were differences on MPV values 
after treatment between the control group 
and the treatment group who got colchi-
cine, in addition, there was a significant 
decrease (delta MPV) between the control 
group and the treatment group. Delta MPV 
was the difference in MPV value before 
treatment and after treatment. Previous 
study on the effect of colchicine on MPV 
was only in mediterranean fever patients, it 
was concluded that the administration of 
colchicine could reduce MPV in mediterra-
nean fever patients (Defetereos et al., 
2013).  
This study was the first study to assess 
the effect of colchicine on decreasing MPV 
in patients with Acute Myocardial Infarc-
tion. This study was in accordance with the 
results of previous studies, which stated 
that the administration of colchicine can 
reduce MPV values in stable CHD patients 
(Yuri et al, 2011; Fox et al, 2013). MPV was 
associated with output in patients with 
acute myocardial infarction (Chu et al., 
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2010). The greater the MPV indicated the 
more reactive of platelets and the less 
responsive to antiplatelet administration 
(Yuri et al,2011). 
It was expected that by reducing MPV, 
it can cause external improvement in pati-
ents with acute myocar infarction. The 
mechanism of the influence of colchicine on 
decreasing MPV was associated with inhi-
bition of IL-6 formation by colchicine (Slo-
bodnick et al., 2015). IL-6 induced changes 
in megakaryocyte maturity resulting in an 
increase in platelet size that can be mea-
sured by MPV (Loo and Martin., 1999). 
This study was also in line with the theore-
tical concept of colchicine which can reduce 
the levels of IL-6 which ultimately caused a 
decrease in MPV. 
This study only focused on suppress-
ing inflammation and the role of platelet 
function in preventing the occurrence of 
morbidity and mortality rates of IMA pati-
ents treated at Dr. Moewardi Hospital. 
Further study was needed from the effects 
of colchicine on clinical outcomes such as 
the occurrence of recurrent acute myocard-
ial infarction, heart failure, or death during 
hospital treatment.   
Based on the results of this study, it 
can be concluded that the administration of 
0.5 mg of Colchicine for 5 days can reduce 
HsCRP and MPV levels in patients with 
acute myocardial infarction. The results of 
this study were expected to provide thera-
peutic options for the management of IMA 
patients. 
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